Description

Novo Nordisk’s 2 Million Prescription Surge — Is Wegovy Rewriting Obesity Care?

Novo Nordisk reported its first quarter 2026 financials and operational updates reflecting a complex interplay of market dynamics, product launches, and ongoing investments. Adjusted sales declined by 4% on a constant exchange rate basis, primarily due to lower realized prices. This was partially offset by volume growth in GLP-1 therapies and expansion in obesity care, with international operations growing 6% while U.S. sales fell 11%. Obesity care sales increased 22% overall, supported by both regions, with the international segment growing 44% driven by volume and market expansion despite pricing pressures in China following competitor price reductions. The company emphasized the robust uptake of the recently launched Wegovy oral pill in the U.S., highlighting 1 million patients treated within 16 weeks and over 2 million total prescriptions since launch. Early data indicate approximately 80% of users were treatment-naive to GLP-1, with limited cannibalization from injectable products.